I recently returned from the 2013 PAGE meeting in Glasgow. As usual, the scientific presentations were some of the best in the field of pharmacometrics. At this year’s meeting I was offered an opportunity to present some of our recent thoughts about model-based drug development in oncology.
Can methods based on existing models really aid decision making in non-small-cell lung cancer (NSCLC) trials?
Posted by
Jonathan French on May 31, 2017 3:46:34 PM
0 Comments Click here to read/write comments